About Event

Why attend the Antigen Specific Immune Tolerance Summit (ASIT)?

Meet representatives from big Pharma, Biotech and Academia at the Antigen-Specific Immune Tolerance Summit 2020 and join a thought-leading platform dedicated to overcoming the complex challenges associated with antigen-specific immunotherapies. Built with an industry-focused agenda, join ASIT 2021 to hear from our largest speaking faculty to date and gain insight from 30+ experts at Pfizer, Merck, Novo Nordisk, Eli Lilly and many more.

The Antigen Specific Immune Tolerance Summit will bring together 100+ industry experts to address the key challenges currently impeding drug development for tolerance inducing therapeutics. Incorporating insights from industry-leading speakers, this conference will delve into the key target discovery, tolerance delivery, and regulatory hurdles that must be addressed for ASIT therapeutics to fulfill their full commercial potential.

This is your comprehensive guide to define your drug development path for 2021. Don’t miss out on your chance to network with industry leaders and join the only industry forum dedicated to driving the progression of your drug development towards the clinic.

Top Reasons to Attend

ASIT Bullet Point

Explore cross learning opportunities and benchmark the progress of your antigen specific drug development against progress in the fields of allergy, oncology and transplantation and gain insights from Epivax and The Immune Tolerance Network

ASIT Bullet Point

Enhance your clinical trial success rate by examining and evaluating current tolerance delivery practices with insights from Merck, Anokion & AdiTxt

ASIT Bullet Point

Examine the fundamental biological controls that determine effective induction of regulatory T cells by better understanding how to successfully induce tolerance with insights from Novo Nordisk, Eli Lilly & Clarivate Analytics

ASIT Bullet Point

Review clinical trial readouts for ASIT therapeutics and explore the fundamental mechanisms that lie behind successful and unsuccessful clinical trial delivery with insights from Cour Therapeutics, Selecta Biosciences & Apitope